Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma

摘要:

The reason why tumors generally have a modest or transient response to antiangiogenic therapy is not well under-stood. This poses a major challenge for sorafenib treatment of advanced hepatocellular carcinoma (HCC) where alternate therapies are lacking. We recently published a paper entitled “Co-option of liver vessels and not sprouting angiogenesis drives acquired sorafenib resistance in hepatocellular carcinoma” in theJournal of the National Cancer Institute, providing a potential explanation for this limited beneift. We found that in mice bearing HCCs that had acquired resistance to sorafenib, tumors had switched from using angiogenesis for growth to co-opting the liver vas-culature by becoming more invasive. Accumulating evidence suggests that many human tumor types may use vessel co-option, which has profound implications for the use of anti-angiogenic agents for cancer treatment.

更多
作者单位:
Sunnybrook Research Institute, 2075 Bayview Avenue, S-Wing, Room S217, Toronto, 0N M4N 3M5, Canada [1]
期刊:
DOI:
10.1186/s40880-016-0162-7
  • 浏览:4
  • 下载:1

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!